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Abstract: 
Clinical trials of small interfering RNA (siRNA) targeting vascular endothelial growth factor-A 
(VEGFA) or its receptor VEGFR1 (also called FLT1), in patients with blinding choroidal 
neovascularization (CNV) from age-related macular degeneration, are premised on gene 
silencing by means of intracellular RNA interference (RNAi). We show instead that CNV 
inhibition is a siRNA-class effect: 21-nucleotide or longer siRNAs targeting non-mammalian 
genes, non-expressed genes, non-genomic sequences, pro- and anti-angiogenic genes, and RNAi-
incompetent siRNAs all suppressed CNV in mice comparably to siRNAs targeting Vegfa or 
Vegfr1 without off-target RNAi or interferon-α/β activation. Non-targeted (against non-
mammalian genes) and targeted (against Vegfa or Vegfr1) siRNA suppressed CNV via cell-
surface toll-like receptor 3 (TLR3), its adaptor TRIF, and induction of interferon-γ and 
interleukin-12. Non-targeted siRNA suppressed dermal neovascularization in mice as effectively 
as Vegfa siRNA. siRNA-induced inhibition of neovascularization required a minimum length of 
21 nucleotides, a bridging necessity in a modelled 2:1 TLR3–RNA complex. Choroidal 
endothelial cells from people expressing the TLR3 coding variant 412FF were refractory to 
extracellular siRNA-induced cytotoxicity, facilitating individualized pharmacogenetic therapy. 
Multiple human endothelial cell types expressed surface TLR3, indicating that generic siRNAs 
might treat angiogenic disorders that affect 8% of the world’s population, and that siRNAs might 
induce unanticipated vascular or immune effects. 
 
Article: 
Therapeutic application of long, double-stranded (ds)RNA-mediated RNAi and sequence-
specific gene silencing through RNAi by short synthetic RNA duplexes is challenging because 
mammalian cells do not uptake ‘naked’ siRNA (whether chemically modified or not) without 
cell-permeating entities1, 2, 3, 4. To minimize systemic exposure, initial clinical trials of siRNA 
were launched using intraocular injection in patients with CNV. CNV, wherein the retina is 
invaded by choroidal vessels beneath the retinal pigmented epithelium (RPE), is a late stage of 
age-related macular degeneration that afflicts 30–50 million people globally. The preclinical 
bases for trials of naked VEGFA siRNA (Bevasiranib) or VEGFR1 siRNA (AGN211745/siRNA-
027) were single reports in mice5, 6 that such siRNAs suppressed laser-injury-induced CNV, a 
model predictive of efficacy in humans7, 8. These findings were interpreted as anomalous 
examples of local delivery surmounting the impediment to intracellular entry9, 10, 11. Instead, we 
show in two animal models that suppression of neovascularization is a generic property of 
siRNAs independent of sequence, target and internalization. 
 
SEQUENCE-INDEPENDENT ANGIOGENESIS SUPPRESSION BY siRNA 
Numerous synthetic non-targeted 21-nucleotide duplex siRNAs from multiple vendors, when 
injected into the vitreous humour of wild-type mice, uniformly and dose-dependently suppressed 
CNV (Fig. 1a, b and Supplementary Fig. 1). siRNAs targeting jellyfish green fluorescent protein 
(Gfp) or firefly luciferase (Luc), non-ocular genes Bglap1 (bone-specific osteocalcin), Cdh16 
(kidney-specific cadherin 16), or Sftpb (lung-
specific surfactant protein B), or non-genomic 
random sequences (RS1–6), all suppressed CNV. 
This stereotypic effect, reproduced independently 
in the laboratories of J.A. and E.S., cannot be 
attributed to ‘off-target’ silencing due to sequence-
specific mismatch tolerance12, nor is it an artefact 
of intraocular delivery because intraperitoneal 
administration of serum-stable 2′O-methyl-Luc-
siRNA suppressed CNV (Supplementary Fig. 2). 
Furthermore, a siRNA with random sequence and 
containing proprietary chemical modifications 
precluding incorporation into RNA-induced 
silencing complex (RISC) also suppressed CNV 
(Fig. 1a), whereas a dsDNA analogue of Luc 
siRNA did not (Supplementary Fig. 3). 
Lipopolysaccharide did not reduce CNV, excluding 
endotoxin contamination as the source of angio-
inhibition; however, nuclease digestion did abolish 
Luc-siRNA-induced CNV suppression. 
Collectively, these data indicate that angio-
inhibition is a siRNA-class effect. 
 
Figure 1: Sequence-independent CNV suppression 
by siRNA through TLR3. 
 
a, siRNAs targeting Gfp, Luc, random sequences (RS1, RS2), Bglap1, Cdh16, 
or Sftpb, and siRNA incapable of RNA-induced silencing (RISC-free), 
suppressed CNV in wild-type mice. n = 8–24; asterisk, P < 0.05 compared to 
no injection, phosphate buffered saline (PBS) and siRNA buffer. b, 
Representative examples of CNV in wild-type eye injected with vehicle 
(buffer) or Luc siRNA (1 μg). c, Gfp siRNA or Luc siRNA suppressed CNV 
in Tlr3+/+ but not Tlr3-/- mice. n = 16–18; asterisk, P < 0.05 compared to 
vehicle (buffer). d, Representative examples of CNV in Gfp-siRNA-injected 
(1 μg) Tlr3+/+ and Tlr3-/- eyes. e, CNV suppression in wild-type mice by Luc siRNA (0.25 μg) was abrogated by soluble TLR3 (sTLR3) but not 
soluble TLR4 or heat-denatured (hd) soluble TLR3 (all 2 μg). n = 8. f, CNV suppression in wild-type mice by Luc siRNA (1 μg) was abrogated 
by neutralizing anti-TLR3 antibodies (Ab; 0.2 μl) but not control IgG (0.2 μl) or chloroquine (Cq; 30 ng). n = 6–8; asterisk, P < 0.05. NS, not 
significant. Vehicle, buffer. All error bars indicate mean ± s.e.m. Scale bars in b, d are 100 μm. 
 
SURFACE TLR3 MEDIATES ANTI-ANGIOGENIC ACTIVITY OF siRNA 
Consistent with reports that naked siRNAs are not internalized by mammalian cells1, 2, 3, 
fluorescein-conjugated Luc siRNA did not enter primary human choroidal endothelial cells 
(CECs) or mouse RPE and CECs (Supplementary Fig. 4). However, fluorescein–Luc-siRNA–
chol, in which cholesterol is conjugated to the 3′ end to enable uptake3, was internalized by 
human and mouse cells, both of which express the mammalian homologue of Sid1, a protein 
involved in internalizing cholesterol-conjugated siRNAs13. We therefore sought a surface 
receptor mediating siRNA-induced angio-inhibition. 
 
We proposed that siRNAs activate TLR3, a long double-stranded viral RNA sensor14, to 
suppress CNV. Indeed, non-targeted siRNAs did not suppress CNV in Tlr3-/- mice (Fig. 1c, d). 
The TLR3 activators polyinosinic:polycytidylic acid (poly(I:C))14 and in-vitro-transcribed long 
dsRNA15 suppressed CNV in wild-type mice, whereas the TLR3 non-activators 
polydeoxyinosinic:polydeoxycytidylic acid (poly(dI:dC))14 and 2-thiouridine (s2U)-modified in-
vitro-transcribed dsRNA15 were ineffective. Poly(I:C) did not suppress CNV in Tlr3-/- mice 
(Supplementary Fig. 5). 
 
Soluble TLR3, but not soluble TLR4 or heat-denatured soluble TLR3, abolished CNV 
suppression by Luc siRNA in wild-type mice (Fig. 1e), suggesting direct interaction of siRNA 
with TLR3. Fluorescein-conjugated Luc siRNA bound wild-type but not Tlr3-/- mouse eye 
sections in situ (Supplementary Fig. 6). Using flow cytometry to monitor binding of fluorescein–
Luc siRNA to the surface of CD31+VEGFR2+ mouse choroidal endothelial cells, greater 
fluorescence was detected on wild-type than Tlr3-/- cells (Supplementary Fig. 7). Pre-incubation 
with soluble TLR3 or competition with poly(I:C) reduced fluorescein–Luc-siRNA binding to 
wild-type mouse CECs. These data extend cell-free system data that 20-nucleotide dsRNAs bind 
TLR3 (refs 16, 17) and support an in vivo siRNA–TLR3 interaction, although we cannot exclude 
accessory molecules enabling TLR3 activation. However, the only such facilitator reported so 
far, CD14 (ref. 18), was dispensable because Luc siRNA suppressed CNV in Cd14-/- mice 
(Supplementary Fig. 8). 
 
CNV suppression by Luc siRNA was blocked by TLR3-neutralizing antibodies (Fig. 1f), 
suggesting that non-targeted siRNA signalled via surface TLR3. We confirmed in vivo surface 
TLR3 expression on mouse and human CECs by flow cytometry and immunofluorescence 
(Supplementary Fig. 9). To resolve the locus of TLR3 activation by siRNA, we used 
chloroquine, which inhibits endosomal TLR3 and TLR9. Chloroquine blocked the increase in 
CNV induced by CpG oligonucleotide, a TLR9 agonist, but did not prevent CNV suppression by 
Luc siRNA (Fig. 1f and Supplementary Fig. 10). Collectively, these data show that surface, not 
endosomal, TLR3 mediates extracellular siRNA-induced angio-inhibition. 
 
Non-targeted siRNAs did not suppress CNV in TrifLps2 mice (Supplementary Fig. 11), which are 
deficient in signalling induced by TRIF (toll/interleukin (IL)-1-receptor-domain-containing 
adaptor-inducing interferon-β), the TLR3 adaptor protein19, 20, confirming TLR3 indispensability. 
TLR3 signalling can diverge at the level of TRIF through a kinase cascade activating interferon 
regulatory factor (IRF)-3 or nuclear factor-κB (NF-κB)21. Non-targeted siRNAs suppressed CNV 
in Irf3-/- but not Nfkb1-/- mice (Supplementary Fig. 11), suggesting a TRIF–NF-κB cascade. 
 
Duplex siRNAs containing immunostimulatory sequences such as UGUGU22 or 
GUCCUUCAA23 trigger off-target effects via TLR7, a single-stranded RNA sensor. However, 
none of our siRNAs contained these sequences (Supplementary Table). Also, non-targeted 
siRNAs suppressed CNV in Tlr7-/- mice (Supplementary Fig. 12). Furthermore, 2′O-methyl-Luc-
siRNA suppressed CNV, excluding TLR7 involvement24. 
 
Although it is improbable that cytosolic dsRNA sensors such as protein kinase R (PKR, encoded 
by Prkra), retinoic-acid-inducible gene 1 (RIG-I), and melanoma differentiation-associated gene 
5 (MDA5)25, 26, 27, 28 are involved in siRNA-mediated angio-inhibition because Luc siRNA did 
not enter cells, we excluded their involvement because siRNA activates PKR when transfected 
into cells29. Luc siRNA suppressed CNV in Prkra-/- just as in wild-type mice, suggesting that 
PKR has no involvement (Supplementary Fig. 13). Poly(I:C12U), an analogue of poly(I:C) that 
activates TLR3 but not MDA5 (ref. 30), suppressed CNV in wild-type mice as effectively as 
poly(I:C) (Supplementary Fig. 5). RIG-I participation is unlikely because in-vitro-transcribed 
dsRNA, which activates RIG-I, and poly(I:C), which does not25, suppressed CNV equally 
(Supplementary Fig. 5). Thus, TLR3 seems to be central to siRNA-induced angio-inhibition. 
 
ANTI-ANGIOGENIC INNATE IMMUNITY TRIGGERED BY siRNA 
siRNAs sometimes induce type I interferon (IFN)22, 23, 29, 31, 32, 33. Although laser injury increased 
levels of IFN-α and IFN-β (IFN-α/β) in the RPE and choroid, they were not further induced by 
Luc siRNA (Supplementary Fig. 14). Luc siRNA suppressed CNV in Ifnar1-/- (IFN-α/β receptor 
null) mice just as in wild-type mice (Fig. 2a). However, type II IFN-γ and IL-12, which are 
TLR3-inducible, were upregulated by Luc siRNA after laser injury (Fig. 2b). Recombinant IFN-γ 
and IL-12 suppressed CNV in wild-type mice (Fig. 2c), consistent with their anti-angiogenic 
properties34. Both were required for angiogenesis suppression because Luc siRNA did not 
suppress CNV in Ifng-/- or Il12a-/- mice (Fig. 2a). 
 
Figure 2: CNV suppression by siRNA is mediated by IFN-γ and IL-12. 
 
a, Luc siRNA (1 μg) suppressed CNV in wild-type and Ifnar1-/- mice but not Ifng-/- or Il12-/- mice. n = 5–10. b, IFN-γ and IL-12 levels in RPE and 
choroid at 24 h after laser injury were higher in wild-type mouse eyes injected with Luc siRNA (1 μg) compared to vehicle-injected eyes. n = 12. 
c, Recombinant IFN-γ or IL-12 reduced CNV in wild-type mice. n = 8. Asterisk, P < 0.05 compared to vehicle (siRNA buffer). All error bars 
indicate mean ± s.e.m. 
 
IFN-γ and IL-12 polarization is congruent with TRIF activation being biased towards NF-κB 
rather than IRF-3. Non-induction of IFN-α/β by synthetic siRNA is consistent with the absence 
of 5′-triphosphates33 and the dominant role of MDA5, which is not involved in siRNA-induced 
angio-inhibition (Supplementary Fig. 5), in mediating dsRNA-induced IFN-α/β (refs 25, 28). 
Alternatively, laser injury might have saturated or inhibited IFN-α/β induction. 
 
TARGETED siRNAs ALSO SUPPRESS CNV VIA TLR3 
We synthesized a siRNA targeting the same sequence as AGN211745 in Vegfr1 (Vegfr1 siRNA, 
complementary to mouse and human sequences). Vegfr1 siRNA suppressed CNV in wild-type 
mice, confirming an earlier report6, but not in Tlr3-/- mice (Fig. 3a), suggesting that it suppressed 
angiogenesis by means of the class effect, not RNAi. Supportive of this, Vegfr1 siRNA 
suppressed CNV as effectively as Luc siRNA in mice that lack the tyrosine kinase domain of 
Vegfr1 (Vegfr1(TK)-/- mice, which have no VEGFR1 signalling35; Supplementary Fig. 15). Also, 
Vegfr1 siRNA did not suppress Vegfr1 mRNA in the RPE and choroid of Tlr3-/- mice 
(Supplementary Fig. 15). Furthermore, Vegfr1-siRNA–chol did not suppress CNV in Tlr3-/- mice 
despite Vegfr1 knockdown (Fig. 3b and Supplementary Fig. 15), consonant with observations 
that VEGFR1 does not promote CNV36. 
 
Figure 3: CNV suppression by targeted siRNAs is mediated by TLR3. 
 
a, hVegfa siRNA and Vegfr1 siRNA suppressed CNV in Tlr3+/+ but not Tlr3-/- mice. b, Vegfr1-siRNA–chol suppressed CNV in Tlr3+/+ but not 
Tlr3-/- mice. n = 5–6. c, hVegfa siRNA and Vegfr1 siRNA, whose anti-sense (as) strands were modified with 5′-methoxy (CH3O) substitution, 
preventing incorporation into RISC, suppressed CNV in Tlr3+/+ but not Tlr3-/- mice. n = 9–14. d, siRNAs targeting mouse (m) or human (h) Vegfa 
reduced CNV in Tlr3+/+ but not in Tlr3-/- mice. mVegfa-siRNA–chol and hVegfa-siRNA–chol suppressed CNV in Tlr3+/+ mice; however, mVegfa-
siRNA–chol but not hVegfa-siRNA–chol suppressed CNV in Tlr3-/- mice. n = 8–10. siRNAs were at 1 μg; asterisk, P < 0.05 compared to vehicle 
(siRNA buffer). All error bars indicate mean ± s.e.m. 
 
CH3O-as-Vegfr1 siRNA (containing 5′-methoxy modification of the anti-sense strand, 
preventing phosphorylation of the 5′-hydroxyl end obligate for RISC incorporation and target 
cleavage37, 38, thereby abolishing RNAi activity) suppressed CNV in wild-type mice as 
effectively as Vegfr1 siRNA and was ineffective in Tlr3-/- mice (Fig. 3c), confirming that Vegfr1 
siRNA suppressed CNV through TLR3, not RNAi. 
 
We also synthesized a siRNA targeting the same sequence as Bevasiranib in human VEGFA 
(hVegfa siRNA, complementary to human VEGFA but mismatched to mouse Vegfa at position 
11, critical for functional targeting39). Both hVegfa siRNA and CH3O-as-hVegfa-siRNA 
suppressed CNV in wild-type but not Tlr3-/- mice (Fig. 3a, c), demonstrating that hVegfa siRNA 
also suppresses CNV through TLR3, not RNAi. hVegfa-siRNA–chol did not suppress CNV in 
Tlr3-/- mice (Fig. 3d), indicating that this siRNA was incapable of functional targeting even after 
internalization due to critical nucleotide mismatch with mouse Vegfa. However, mVegfa-siRNA–
chol (complementary to mouse Vegfa) suppressed CNV in Tlr3-/- mice. As further confirmation 
of the centrality of this nucleotide, mVegfa-siRNA–chol, but not hVegfa-siRNA–chol, 
suppressed Vegfa in the RPE and choroid of Tlr3-/- mice (Supplementary Fig. 16). Hence, 
siRNAs unaided by cell permeation cannot execute RNAi. 
 
Luc siRNA suppressed CNV (51 ± 7%) in wild-type mice as effectively as mVegfa-siRNA–chol 
in Tlr3-/- mice (41 ± 11%; Fig. 3d) and anti-VEGFA neutralizing antibodies in wild-type mice 
(49 ± 7%; Supplementary Fig. 17), suggesting that TLR3 activation is as effective as VEGFA 
blockade, the current standard of care. Luc siRNA did not affect Vegfa, Vegfr1, or Vegfr2 mRNA 
levels in wild-type mice (Supplementary Fig. 18), so activity seems to be independent of 
VEGFA pathways. Despite the potential for mVegfa-siRNA–chol to activate TLR3 and 
knockdown Vegfa in wild-type mice, there was no angio-inhibitory synergy. This could be 
attributed to blockade of VEGFA-dependent signalling by IFN-γ (induced by siRNA) and 
potential crosstalk40. Indeed, CNV suppression by Luc siRNA or recombinant IFN-γ was not 
enhanced by co-administration of anti-VEGFA antibodies, consistent with convergence of anti-
angiogenic mechanisms (Supplementary Fig. 18). Alternatively, incorporation of mVegfa-
siRNA–chol into RISC might preclude TLR3 interaction. 
 
Neither hVegfa siRNA nor Vegfr1 siRNA suppressed CNV in Ifng-/- or Il12a-/- mice 
(Supplementary Fig. 19), confirming that these targeted siRNAs suppressed CNV via the class 
effect, not RNAi. As an additional demonstration that siRNA suppresses CNV without target 
cleavage, Irf3 siRNA suppressed CNV in Irf3-/- mice as effectively as Luc siRNA 
(Supplementary Fig. 20), and Tlr3 siRNA suppressed CNV in wild-type mice without Tlr3 
knockdown. This class effect was so robust that siRNA targeting Il12, which is anti-angiogenic 
in this model, also suppressed CNV in wild-type but not Tlr3-/- mice (Fig. 2c and Supplementary 
Fig. 21). These data demonstrate that non-targeted and targeted siRNA, without active 
intracellular delivery, suppressed CNV by means of extracellular TLR3 activation. 
 
MINIMUM LENGTH OF siRNA REQUIRED TO SUPPRESS CNV 
The minimum length of dsRNA activating TLR3 in vivo is unclear. We found, unlike 21- and 23-
nucleotide Luc siRNA, 7-, 13-, 16-, or 19-nucleotide versions did not suppress CNV (Fig. 4a). 
This, coupled with data that longer duplexes such as ~1,000-nucleotide dsRNA and poly(I:C) 
suppressed CNV (Supplementary Fig. 5), suggest that at least 21 nucleotides are required to 
activate TLR3. To understand the structural basis of the divergence between 19 and 21 
nucleotides, we performed docking simulations between dimeric TLR3, which is required for 
signalling17, 41, 42, and dsRNA using crystal structures of TLR3 and 19-nucleotide dsRNA, the 
latter being shortened or extended as necessary. 
 
 
Figure 4: Minimum length for TLR3 activation. 
 
a, 21-nucleotide or 23-nucleotide Luc siRNA but not truncated versions suppressed CNV in wild-type mice. n = 8–11; asterisk, P < 0.05 
compared to vehicle (buffer); mean ± s.e.m. Equimolar amounts to 1 μg of 21-nucleotide Luc siRNA. nt, nucleotide. b, c, Orthogonal views of a 
model of TLR3 ectodomain dimer (green and cyan subunits shown as backbone ribbons) with computer-docked 21-nucleotide dsRNA. Protein 
modules interact via C-terminal domains to form a highly symmetrical dimer. The model incorporated potential interactions involving a larger set 
of TLR3 residues considered important in RNA binding (displayed as purple and red side chains on ectodomain subunits); these residues were 
within 4.5 Å of RNA. d, TLR3 dimer with docked 19-nucleotide dsRNA shows proximity to fewer putative RNA-binding residues. Binding of 
19-nucleotide dsRNA was less favourable than 21-nucleotide dsRNA (ΔE = –308 kcal mol-1; 95% confidence interval: 261–355; n = 5; P = 
0.008). 
 
Docking of dsRNA of various lengths on a TLR3 ectodomain (ECD) monomer did not clarify 
the observed minimal length requirement for TLR3 activation because the ECD solenoid is 
approximately the same width as a single turn of an RNA helix. Therefore, a TLR3 monomer 
cannot discriminate between dsRNAs greater than about 10 nucleotides in length (data not 
shown), indicating that TLR3 dimerization is required for the observed length needed for 
activation. We developed a model of a 2:1 TLR3–dsRNA complex, constrained by these 
observations or interpretations of known data: (1) active TLR3 involves a specific ECD carboxy 
terminus dimer, formation of which is stabilized by dsRNA binding17, 41, 42; (2) TLR3 residues 
most critical for RNA binding and receptor activation, H539 and N541 (ref. 41), lie in a region 
40–45 Å from the ECD C terminus; (3) dsRNA of 21 nucleotides or longer is required for 
receptor activation (Fig. 4a), suggesting that a dsRNA of approximately two full helical turns 
(~50 Å in length) is required to span clusters of RNA-binding residues on two TLR3 monomers. 
 
We proposed that C terminus dimerization of TLR3 ECDs creates a scaffold for RNA binding in 
which clusters of functional RNA-binding residues are separated by approximately 50 Å. This is 
possible with significant overlap of the C terminus domains, as would be required for effective 
dimerization. 
 
Using these constraints, computer docking identified a highly symmetrical C terminus dimer of 
TLR3 ECD with clusters of RNA-binding residues on the same side of the complex and spaced 
appropriately (N541 to N541 distance of 50 Å). This dimer was used to dock either 21-nucleotide 
or 19-nucleotide dsRNA, under the constraint that docked complexes place H539 and N541 on 
both TLR3 monomers within 5 Å of RNA and be as symmetrical as possible43. The resulting 2:1 
complexes (Fig. 4b–d) were subjected to short molecular dynamics simulations, from which five 
time points were sampled and energy minimized, indicating that the 21-nucleotide complex was 
approximately 300 kcal mol-1 energetically more favourable than the 19-nucleotide complex. 
This is consistent with experimental results showing a loss in anti-angiogenic activity for dsRNA 
with fewer than 21-nucleotides (Fig. 4a). Furthermore, 19-nucleotide dsRNA was unable to 
make contact with as many of the putative RNA-binding residues as 21-nucleotide dsRNA (Fig. 
4c, d and Supplementary Figs 22 and 23). The model also allows for binding of longer dsRNAs 
such as poly(I:C). 
 
We considered possible interactions between dsRNA and an extended set of putative RNA-
binding residues including, in addition to H539 and N541, E442, N466, K467, R489, N515, 
N516, N517, N540 and N572 (refs 17, 44). Compared to 19-nucleotide dsRNA, 21-nucleotide 
dsRNA made contact (within 4.5 Å) with 80% more side chains. Thus, this model accords with 
the possibility that these TLR3 residues may contribute in varying degrees to RNA binding, if 
not actual receptor activation. 
 
This model predicts that although siRNAs shorter than 21 nucleotides cannot bridge functional 
residues on TLR3 dimers, they can bind just as well as longer siRNAs to TLR3 monomers (Fig. 
4d and Supplementary Fig. 23). Indeed, excess 19-nucleotide Luc siRNA prevented CNV 
suppression by 21-nucleotide Luc siRNA (Supplementary Fig. 24) in a dose-dependent manner, 
suggesting that the shorter siRNA can be an inactive competitor by saturating binding sites on 
TLR3 monomers and interfere with the ability of longer siRNAs to bridge two monomers to 
form the active dimeric signalling complex. The specificity of this competition was demonstrated 
by the inability of a dsDNA analogue of 19-nucleotide Luc siRNA to interfere with CNV 
suppression by 21-nucleotide Luc siRNA. 
 
CLINICAL IMPLICATIONS 
Of the known non-synonymous single-nucleotide polymorphisms (SNPs) in TLR3, two (N284I, 
rs5743316 and L412F, rs3775291) are hypomorphic (associated with a reduction in cell surface 
expression and functional activation of receptor)45. Variance for rs3775291 is prevalent in many 
populations (minor allele frequency ranges from 0.26 to 0.40 in Asian and European samples) 
whereas variance for rs5743316 is rare (minor allele frequency <0.01). Therefore we sought to 
determine whether non-targeted siRNA therapy would have differential effects on patients with 
different homozygous genotypes at rs3775291 (we did not identify any patients with variance at 
rs5743316). We scanned a library of primary human CECs isolated from single donors for cells 
homozygous at rs3775291. To determine the fate of these cells when exposed to extracellular 
non-targeted siRNA, we assayed their survival in serum-supplemented culture in the presence of 
serum-stable 2'O-methyl-Luc-siRNA without transfection reagents. Non-targeted siRNA induced 
a 38% reduction in survival of 412LL human CECs (consistent with known cytotoxic effects of 
TLR3 activation), but a 3% increase in that of 412FF human CECs (Supplementary Fig. 25), 
suggesting that the TLR3 412 genotype is an important determinant of the cell survival response 
to siRNA and consistent with TLR3-mediated angio-inhibition. However, further confirmation is 
required to assign differential survival solely to this SNP and to support a role for 
pharmacogenetic testing of patients before initiating siRNA therapeutics. Apart from CECs, 
pericytes and leukocytes have critical roles in angiogenesis; defining their contributions awaits 
the development of tissue-specific TLR3 knockouts. 
 
To determine the potential for siRNA-induced angio-inhibition in other organs, we interrogated 
human endothelial cells from aorta, dermis, lung and umbilical vein for TLR3 expression. 
Surface TLR3 was detected on all of these cells (Supplementary Fig. 26). Serum-stable 21-
nucleotide 2′O-methyl-Luc-siRNA, but not a 7-nucleotide version, suppressed dermal 
angiogenesis induced by excisional wounding in wild-type mice as effectively as 21-nucleotide 
2′O-methyl-mVegfa-siRNA (Supplementary Fig. 27), recapitulating the length-dependent anti-
angiogenic class effect of siRNA in CNV. The broad angio-inhibitory effect of siRNA and 
widespread surface expression of TLR3 on endothelial cells suggest that people with the 412LL 
genotype might be suitable candidates for exploring the anti-angiogenic utility of non-targeted 
siRNA, whereas targeted cell-permeating siRNA therapies would be better suited for 412FF 
individuals. Analysing SNPs of genes downstream from TLR3 might yield refined genomic 
profiles predictive of response to targeted and non-targeted siRNAs. 
 
DISCUSSION 
Our results demonstrate that 21-nucleotide or longer dsRNAs are anti-angiogenic. We show that 
two investigational siRNAs in clinical trials owe their anti-angiogenic effect in mice not to target 
knockdown but to TLR3 activation. Our findings support investigations of non-targeted dsRNAs 
as generic anti-CNV agents as effective as anti-VEGFA antibodies, the current standard of care8, 
while avoiding potential neurotoxicity resulting from chronic administration of the latter46. 
 
Our docking model, although not a high-resolution structure, confirms a potential interaction 
between 21-nucleotide siRNA and TLR3, and structurally explains TLR3’s remarkable length-
based discrimination of dsRNAs. Although duplexes shorter than 21 nucleotides did not suppress 
CNV, our model suggests that they could interact with TLR3 with a free energy of binding 
below the threshold for dimer stabilization and receptor activation. Such discrimination between 
interaction and activation, if it exists, might also be attributed to unknown accessory proteins that 
chaperone siRNA to TLR3. An outstanding question is whether differential binding to 
monomeric versus active signalling dimeric TLR3 underlies the divergence between 21-
nucleotide and shorter siRNAs. 
 
Tlr3+/+ and Tlr3–/– mice exhibited similar CNV responses in the absence of exogenous dsRNAs, 
suggesting that TLR3 was dispensable to basal angiogenesis and that endogenous dsRNAs (for 
example, microRNAs) do not activate TLR3 or influence angiogenesis in this model. Elucidating 
the discriminants among potential TLR3 ligands will advance understanding of self/non-self 
immune recognition. 
 
It is tempting to speculate that TLR3 activation and anti-angiogenic dampening by viral 
transcripts abundant in the human retina–choroid interface (G. S. Hageman, personal 
communication) might explain why few patients with early age-related macular degeneration 
undergo the angiogenic switch despite the onslaught of inflammatory stimuli that promote 
CNV47. Similarly, investigations of SNPs in TLR3 and downstream genes might prove fruitful in 
revealing new risk-conferring and protective alleles for CNV and atrophic age-related macular 
degeneration, and predict efficacy of angiogenesis inhibition and susceptibility to adverse 
vascular effects. 
 
Further studies will determine whether siRNAs, apart from inducing (un)desirable effects on the 
vasculature, also influence TLR3-mediated antimicrobial immune responses and non-canonical 
adverse effects of TLR3 activation on pregnancy48, immune privilege49 and neuronal growth50, 
especially when delivered systemically. Judicious approaches to enhance therapeutic specificity 
include modifications abrogating TLR3 activation and reducing lengths below 21 nucleotides. 
Conversely, genomic fingerprinting of patients could hasten angio-inhibitory applications of 
generic siRNA while avoiding hazards of specific gene targeting. 
 
METHODS SUMMARY 
Laser photocoagulation was performed to induce CNV in mice as previously described36, 47. 
CNV volumes were measured by scanning laser confocal microscopy using fluorescein-
isothiocyanate-conjugated Griffonia simplicifolia isolectin B4 (Vector Laboratories), and 
compared by hierarchical logistic regression using repeated measures analysis. Chemical siRNA 
sequences for treatments were purchased from Dharmacon or Ambion, Inc. Sense and anti-sense 
strands of siRNA were annealed per the manufacturer’s instructions, formulated in either sterile 
siRNA buffer (Dharmacon) or nuclease-free PBS, and injected into the vitreous cavity in a total 
volume of 1 μl with a 33-gauge Exmire microsyringe (Ito Corporation). The docked complex 
structures were obtained through rigid-body docking using a modified version of the program 
FTDock with the X-ray structures of TLR3 ligand-binding domain (Protein Data Bank (PDB) 
entry 2A0Z) and a 19-nucleotide RNA duplex (PDB entry 1QC0) as the initial structures, the 
latter being shortened or extended as necessary to generate various lengths of dsRNA with 2-
nucleotide overhangs at each end. Final docked 2:1 TLR3–dsRNA complexes were subjected to 
a short minimization and an implicit solvent molecular dynamics simulation to refine the 
structures, which were then used for energy calculations. Application of biological information 
as described above greatly improved the docking results by constraining the sampling space and 
generating models consistent with the experimental binding data. 
 
REFERENCES 
1. Chiu, Y. L., Ali, A., Chu, C. Y., Cao, H. & Rana, T. M. Visualizing a correlation between 
siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol. 11, 1165–1175 
(2004)  
2. Saleh, M. C. et al. The endocytic pathway mediates cell entry of dsRNA to induce RNAi 
silencing. Nature Cell Biol. 8, 793–802 (2006)  
3. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration 
of modified siRNAs. Nature 432, 173–178 (2004)  
4. Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface 
receptors. Nature Biotechnol. 23, 709–717 (2005)  
5. Reich, S. J. et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular 
neovascularization in a mouse model. Mol. Vis. 9, 210–216 (2003)  
6. Shen, J. et al. Suppression of ocular neovascularization with siRNA targeting VEGF receptor 
1. Gene Ther. 13, 225–234 (2006)  
7. Krzystolik, M. G. et al. Prevention of experimental choroidal neovascularization with 
intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 
120, 338–346 (2002)  
8. Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N. 
Engl. J. Med. 355, 1419–1431 (2006)  
9. Corey, D. R. RNA learns from antisense. Nature Chem. Biol. 3, 8–11 (2007)  
10. de Fougerolles, A., Vornlocher, H. P., Maraganore, J. & Lieberman, J. Interfering with 
disease: a progress report on siRNA-based therapeutics. Nature Rev. Drug Discov. 6, 443–
453 (2007)  
11. Rana, T. M. Illuminating the silence: understanding the structure and function of small 
RNAs. Nature Rev. Mol. Cell Biol. 8, 23–36 (2007) 
12. Jackson, A. L. et al. Expression profiling reveals off-target gene regulation by RNAi. Nature 
Biotechnol. 21, 635–637 (2003) 
13. Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. 
Nature Biotechnol. 25, 1149–1157 (2007)  
14. Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double-stranded 
RNA and activation of NF- B by Toll-like receptor 3. Nature 413, 732–738 (2001)  
15. Kariko, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-
like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. 
Immunity 23, 165–175 (2005)  
16. Bell, J. K. et al. The molecular structure of the Toll-like receptor 3 ligand-binding domain. 
Proc. Natl Acad. Sci. USA 102, 10976–10980 (2005)  
17. Ranjith-Kumar, C. T. et al. Biochemical and functional analyses of the human Toll-like 
receptor 3 ectodomain. J. Biol. Chem. 282, 7668–7678 (2007)  
18. Lee, H. K., Dunzendorfer, S., Soldau, K. & Tobias, P. S. Double-stranded RNA-mediated 
TLR3 activation is enhanced by CD14. Immunity 24, 153–163 (2006)  
19. Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor 
signaling pathway. Science 301, 640–643 (2003) 
20. Hoebe, K. et al. Identification of Lps2 as a key transducer of MyD88-independent TIR 
signalling. Nature 424, 743–748 (2003)  
21. Jiang, Z., Mak, T. W., Sen, G. & Li, X. Toll-like receptor 3-mediated activation of NF- B 
and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN- . Proc. 
Natl Acad. Sci. USA 101, 3533–3538 (2004)  | 
22. Judge, A. D. et al. Sequence-dependent stimulation of the mammalian innate immune 
response by synthetic siRNA. Nature Biotechnol. 23, 457–462 (2005) 
23. Hornung, V. et al. Sequence-specific potent induction of IFN-  by short interfering RNA in 
plasmacytoid dendritic cells through TLR7. Nature Med. 11, 263–270 (2005)  
24. Judge, A. D., Bola, G., Lee, A. C. & MacLachlan, I. Design of noninflammatory synthetic 
siRNA mediating potent gene silencing in vivo. Mol. Ther. 13, 494–505 (2006)  
25. Kato, H. et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA 
viruses. Nature 441, 101–105 (2006)  
26. Meurs, E. et al. Molecular cloning and characterization of the human double-stranded RNA-
activated protein kinase induced by interferon. Cell 62, 379–390 (1990)  
27. Yoneyama, M. et al. The RNA helicase RIG-I has an essential function in double-stranded 
RNA-induced innate antiviral responses. Nature Immunol. 5, 730–737 (2004)  
28. Gitlin, L. et al. Essential role of mda-5 in type I IFN responses to 
polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl 
Acad. Sci. USA 103, 8459–8464 (2006)  
29. Sledz, C. A., Holko, M., de Veer, M. J., Silverman, R. H. & Williams, B. R. Activation of the 
interferon system by short-interfering RNAs. Nature Cell Biol. 5, 834–839 (2003)  
30. Gowen, B. B. et al. TLR3 is essential for the induction of protective immunity against Punta 
Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): 
differential recognition of synthetic dsRNA molecules. J. Immunol. 178, 5200–5208 (2007)  
31. Heidel, J. D., Hu, S., Liu, X. F., Triche, T. J. & Davis, M. E. Lack of interferon response in 
animals to naked siRNAs. Nature Biotechnol. 22, 1579–1582 (2004)  
32. Kariko, K., Bhuyan, P., Capodici, J. & Weissman, D. Small interfering RNAs mediate 
sequence-independent gene suppression and induce immune activation by signaling through 
toll-like receptor 3. J. Immunol. 172, 6545–6549 (2004)  
33. Kim, D. H. et al. Interferon induction by siRNAs and ssRNAs synthesized by phage 
polymerase. Nature Biotechnol. 22, 321–325 (2004)  
34. Voest, E. E. et al. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl Cancer Inst. 87, 
581–586 (1995)  
35. Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. & Shibuya, M. Flt-1 lacking the tyrosine 
kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl 
Acad. Sci. USA 95, 9349–9354 (1998)  
36. Nozaki, M. et al. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a 
novel antiangiogenic activity of VEGF-A. J. Clin. Invest. 116, 422–429 (2006)  
37. Nykanen, A., Haley, B. & Zamore, P. D. ATP requirements and small interfering RNA 
structure in the RNA interference pathway. Cell 107, 309–321 (2001)  
38. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R. & Tuschl, T. Single-stranded 
antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563–574 (2002)  
39. Birmingham, A. et al. 3' UTR seed matches, but not overall identity, are associated with 
RNAi off-targets. Nature Methods 3, 199–204 (2006)  
40. Battle, T. E., Lynch, R. A. & Frank, D. A. Signal transducer and activator of transcription 1 
activation in endothelial cells is a negative regulator of angiogenesis. Cancer Res. 66, 3649–
3657 (2006)  
41. Bell, J. K., Askins, J., Hall, P. R., Davies, D. R. & Segal, D. M. The dsRNA binding site of 
human Toll-like receptor 3. Proc. Natl Acad. Sci. USA 103, 8792–8797 (2006)  
42. Choe, J., Kelker, M. S. & Wilson, I. A. Crystal structure of human toll-like receptor 3 
(TLR3) ectodomain. Science 309, 581–585 (2005)  
43. Gay, N. J., Gangloff, M. & Weber, A. N. Toll-like receptors as molecular switches. Nature 
Rev. Immunol. 6, 693–698 (2006)  
44. Takada, E. et al. C-terminal LRRs of human Toll-like receptor 3 control receptor 
dimerization and signal transmission. Mol. Immunol. 44, 3633–3640 (2007)  
45. Ranjith-Kumar, C. T. et al. Effects of single nucleotide polymorphisms on Toll-like Receptor 
3 activity and expression in cultured cells. J. Biol. Chem. 282, 17696–17705 (2007)  
46. Nishijima, K. et al. Vascular endothelial growth factor-A is a survival factor for retinal 
neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. 
Pathol. 171, 53–67 (2007)  
47. Nozaki, M. et al. Drusen complement components C3a and C5a promote choroidal 
neovascularization. Proc. Natl Acad. Sci. USA 103, 2328–2333 (2006)  
48. Lin, Y., Liang, Z., Chen, Y. & Zeng, Y. TLR3-involved modulation of pregnancy tolerance 
in double-stranded RNA-stimulated NOD/SCID mice. J. Immunol. 176, 4147–4154 (2006)  
49. Lang, K. S. et al. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 
signaling. J. Clin. Invest. 116, 2456–2463 (2006)  
50. Cameron, J. S. et al. Toll-like receptor 3 is a potent negative regulator of axonal growth in 
mammals. J. Neurosci. 27, 13033–13041 (2007)  
51. Muller, U. et al. Functional role of type I and type II interferons in antiviral defense. Science 
264, 1918–1921 (1994)  
52. Sato, M. et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in 
response to viruses for IFN- /  gene induction. Immunity 13, 539–548 (2000)  
53. Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-
dependent signaling pathway. Nature Immunol. 3, 196–200 (2002)  
54. Zhang, L. et al. Different effects of glucose starvation on expression and stability of VEGF 
mRNA isoforms in murine ovarian cancer cells. Biochem. Biophys. Res. Commun. 292, 
860–868 (2002)  
55. Smith, J. R. et al. Unique gene expression profiles of donor-matched human retinal and 
choroidal vascular endothelial cells. Invest. Ophthalmol. Vis. Sci. 48, 2676–2684 (2007)  
 
ACKNOWLEDGEMENTS 
We thank collaborators for gifts of knockout mouse strains; R. King, L. Xu and K. Emerson for 
technical assistance; R. Mohan, S. Bondada, R. A. Brekken, M. W. Fannon, T. S. Khurana, B. J. 
Raisler, P. A. Pearson, J. E. Springer, J. G. Woodward, A. M. Rao, G. S. Rao and K. Ambati for 
discussions; and C. Liu and R. J. Kryscio for statistical guidance. J.A. was supported by 
NEI/NIH, Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, 
Macula Vision Research Foundation (MVRF), E. Matilda Ziegler Foundation for the Blind, Dr. 
E. Vernon Smith and Eloise C. Smith Macular Degeneration Endowed Chair, Lew R. 
Wassermann Merit (LRWM) and Physician Scientist Awards (Research to Prevent Blindness 
(RPB)), American Health Assistance Foundation, University of Kentucky University Research 
Professorship, and departmental challenge grant from RPB; A.T. by Japan Society for the 
Promotion of Science for Young Scientists; R.J.C.A. by RPB Medical Student Fellowship; K.Z. 
by NEI/NIH, RPB LRWM award, MVRF and VA Merit Award; B.A. by Clayton Foundation for 
Research; J.R.S. by NEI/NIH and RPB Career Development Award; B.K.A. by NEI/NIH, VA 
Merit Award, and Department of Defense; and E.W.T. by NC Biotechnology Center. 
 
AUTHOR CONTRIBUTIONS 
M.E.K., K.Y., A.T., M.N., J.Z.B., R.J.C.A., S.I., M.I. and E.S. performed CNV experiments. T.A.W. 
and L.A.D. performed dermal experiments. V.C. and E.W.T. performed modelling simulations. 
Y.P, B.A. and J.R.S. performed cytotoxicity experiments. D.G., Z.Y. and K.Z. performed 
genotyping. K.K. provided reagents. J.A. conceived and directed the project, and, with assistance 
from E.W.T., B.K.A., K.K., B.A. and J.R.S., wrote the paper. All authors had the opportunity to 
discuss the results and comment on the manuscript. 
 
ONLINE METHODS 
Animals 
C57BL/6J, Ifng-/-, Il12a-/-, Nfkb1-/-, Tlr3-/-, Tlr3+/+ and TrifLps2 mice were purchased from The 
Jackson Laboratory. Vegfr1(TK)-/-, Ifnar1-/- (gift from H. W. Virgin), Irf3-/- (gift from T. 
Taniguchi via M. David), Prkra-/- (gift from R. H. Silverman via G. Luo) and Tlr7-/- (obtained 
from S. Akira via D. A. Golenbock) mice have been previously described35, 51, 52, 53. 
 
 
CNV 
Laser photocoagulation ( OcuLight GL, IRIDEX) was performed on both eyes of each 6–8-
week-old mice to induce CNV as previously described36, 47. CNV volumes were measured by 
scanning laser confocal microscopy ( TCS SP, Leica) as reported36, 47 with 0.5% FITC-
conjugated Isolectin B4 (Vector). Results are expressed as mean ± s.e.m. with P < 0.05 
considered statistically significant. 
 
Drug treatments 
siRNAs formulated in siRNA buffer (Dharmacon) or PBS (Sigma-Aldrich), chloroquine 
(Invivogen), poly(I:C) (Invivogen), poly(dI:dC) (Invivogen), poly(I:C12U) (Ampligen; 
Bioclones), and recombinant soluble mouse TLR3 (R&D Systems), mouse soluble TLR4 (R&D 
Systems), neutralizing rat antibodies against mouse TLR3 (eBioscience; ref. 48), 
immunostimulatory CpG oligodeoxynucleotide (ODN), GpC ODN (Invivogen), recombinant 
IFN-γ (Peprotech), recombinant IL-12 (eBioscience), neutralizing rat antibodies against mouse 
IL-12 (R&D Systems) and isotype control IgGs (R&D Systems or eBioscience as appropriate) 
were dissolved in PBS and injected into the vitreous cavity in a total volume of 1 μl. In some 
experiments, siRNA or vehicle was injected intraperitoneally. 
 
siRNA 
Chemical siRNA sequences and modifications are listed in the Supplementary Table. All 
siRNAs except RS3–RS6 (Ambion) were purchased from Dharmacon. 
 
Protein expression 
ELISAs were used to quantify IFN-α/β/γ (PBL) with normalization to total protein (Bio-Rad). 
 
Gene expression 
Real-time reverse transcriptase PCR (RT–PCR) was performed ( Realplex, Eppendorf) on total 
mouse RPE and choroid RNA ( RNAqueous, Ambion). Primers and Taqman probes for Vegfa 
were described in ref. 54. SYBR green was used for all other assays. Primers for TLR3 were 
purchased (Superarray), and were custom designed for Vegfr1 and Vegfr2 (Supplementary 
Methods). 
 
Flow cytometry 
For surface TLR3 staining, human CECs, isolated as previously reported55, human aortic 
endothelial cells (HAECs; gift from E. Reed), human pulmonary artery endothelial cells 
(HPAECs; Clonetics), human dermal microvascular endothelial cells (HDMECs; Clonetics) and 
human umbilical vein endothelial cells (HUVECs; Clonetics) cultivated in MCDB-131 media 
(Gibco) with EGM-2MV (omitting gentamicin, hydrocortisone, Clonetics) were blocked and 
incubated with PE-conjugated anti-human TLR3 (20 μg ml-1, Imgenex) and FITC-conjugated 
CD31 (BD Biosciences). For intracellular TLR3 staining, FITC–CD31-labelled cells were fixed 
and permeabilized with Leucoperm (Serotec) and stained for TLR3 in the presence of 10% 
mouse serum. PE-conjugated mouse IgGκ1 isotype served as control (BD Biosciences). Samples 
were analysed on a FACSCalibur (Becton Dickinson) with a minimum of 10,000 events using 
Kolmogorov–Smirnov statistics. 
 
Suspensions of C57BL/6J RPE and choroid cells (106) were isolated 1 day after laser injury and 
incubated with APC anti-mouse CD31 antibody (20 μg ml-1, BD Biosciences) and PE anti-mouse 
VEGFR2 antibody (20 µg ml-1; BD Biosciences). For surface TLR3 staining, cells were 
incubated with anti-mouse TLR3 (10 μg ml-1, R&D Systems) that was pre-conjugated to Alexa 
Fluor 488 (Invitrogen). For intracellular TLR3 staining, CD31/VEGFR2-labelled cells were 
subjected to fixation and permeabilization followed by incubation with anti-mouse TLR3 
(5 μg ml-1). FITC-conjugated rat IgG2a isotype (BD Biosciences) served as a control. 
 
Fluorescein–siRNA interaction assays 
CD31/VEGFR2-labelled RPE and choroid cells (106) isolated from C57BL/6J or Tlr3-/- mice 
1 day after laser injury were incubated with fluorescein–Luc-siRNA (100 μg ml-1) for 30 min on 
ice. To determine the specificity Luc siRNA binding to TLR3, fluorescein–Luc-siRNA was pre-
incubated with either soluble TLR3, TLR4, poly(I:C), or poly(dI:dC). 
 
Fluorescein–siRNA uptake in mouse RPE and choroid cells 
C57BL/6J RPE and choroid cells (106) were harvested immediately after laser injury, incubated 
with 21-nucleotide fluorescein–Luc-siRNA, 21-nucleotide fluorescein–Luc-siRNA–chol (both 
100 μg ml-1) or PBS vehicle in phenol-free M199 media (Gibco) plus 10% FBS for 1 h at 37 °C 
and treated with 150 μl of 0.05% trypsin (Gibco) for 3 min at 37 °C to remove extracellular 
siRNA. 
 
Immunofluorescent microscopy 
Human CECs (105) were incubated with 21-nucleotide fluorescein–Luc-siRNA or 21-nucleotide 
fluorescein–Luc-siRNA–chol (both 100 μg ml-1) for 1 h at 37 °C. 
 
Fluorescein–siRNA binding in mouse RPE and choroid tissue 
Frozen sections of C57BL/6J or Tlr3-/- mice prepared 3 days after laser injury and intravitreous 
injection of Luc siRNA (1 μg) were blocked with 3% BSA and incubated with 21-nucleotide 
fluorescein–Luc-siRNA (10 μg ml-1) for 1 h at 37 °C. Slides were fixed with 4% PFA, blocked in 
10% normal rabbit serum, incubated with rabbit anti-FITC antibody (1:100, Zymed) overnight at 
4 °C followed by anti-rabbit Alexa Fluor 488 (1:200, Invitrogen). 
 
TLR3 localization 
C57BL/6J mouse eye sections (10 μm) were fixed in ice-cold acetone for 10 min at 4 °C, 
blocked, and incubated with rabbit anti-mouse TLR3 (1:50, Imgenex) overnight at 4 °C followed 
by Alexa Fluor 594 goat anti-rabbit IgG (1:200, Invitrogen) For co-labelling of CECs, sections 
were incubated with rat anti-mouse CD31 (1:50, BD Biosciences) followed by goat anti-rat IgG 
conjugated to Alexa Fluor 488 (1:200). Human CECs, isolated from donated eyes using anti-
CD31 antibody-coated magnetic beads (BD Biosciences and Invitrogen, respectively) as 
previously described55, were grown in chamber slides (Lab-Tek). For surface staining, cells were 
blocked with PBS-1% BSA and incubated with mouse anti-human TLR3 (20 μg ml-1, 
eBioscience). For surface membrane co-localization, cells were stained with rabbit anti-CD46 
(1:50, Santa Cruz). Goat anti-mouse Alexa Fluor 488 and donkey anti-rabbit Cy3 (both 1:400) 
were used as secondary antibodies. Mouse IgGκ1 isotype antibody (20 μg ml-1, eBioscience) 
served as a control. 
 
